Table 1.

Patient and Tumor Characteristics, FOLFOX-Only and FOLFOX v FU + LV Trials

Variable	FOLFOX-Only Trials		FOLFOX v FU + LV Trials
			FU + LV		FOLFOX		P
	No.	%	No.	%	No.	%
Age, years							.94
< 50	1,993	22	621	19	622	19
50+	7,000	78	2,619	81	2,606	81
Sex							.64
Male	4,737	53	1,769	55	1,782	55
Female	4,256	47	1,471	45	1,446	45
Race							.16
White	7,885	88	2,951	91	2,897	90
Black	544	6	105	3	113	4
Other	533	6	182	6	216	7
NA	31	0	2	0	2	0
PS							.04
0	7,165	80	2,716	84	2,640	82
1+	1,816	20	520	16	581	18
NA	12	0	4	0	7	0
Location							.05
S, left	3,540	46	1,155	51	1,067	47
S, right	2,851	37	735	32	792	35
S, trans	1,358	18	375	17	390	17
NA	1,244	14	975	30	979	31
Grade							.39
Low	7,031	79	2,596	83	2,633	84
High	1,847	21	528	16	504	16
NA	115	1	116	6	91	3
Stage							.86
Stage II	1,453	16	798	25	802	25
Stage III	7,540	84	2,442	75	2,426	75
T-stage							.61
T1/T2	1,073	12	313	10	289	9
T3	6,848	77	2,494	77	2,511	78
T4	1,028	11	427	13	425	13
NA	44	0	6	0	3	0
N-stage							.93
N0	1,454	16	797	25	802	25
N1a	2,153	24	769	24	749	23
N1b	2,473	28	812	25	825	26
N2a	1,669	19	518	16	525	16
N2b	1,241	14	341	11	324	10
NA	3	0	3	0	3	0
Total	8,993	100	3,240	100	3,228	100	—

Abbreviations: FOLFOX, infusional fluorouracil, leucovorin, oxaliplatin; FU + LV, fluorouracil plus leucovorin; NA, not applicable; PS, performance status; S, single.